-
Therapeutics and Clinical Risk Management
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Methotrexate-induced cutaneous ulceration in patients with erythrodermic mycosis fungoides
Review
(1891) Views (473) Full article downloads
Authors: Debra L Breneman, Timothy J Storer, John C Breneman, Diya F Mutasim
Published Date August 2008
Volume 2008:4(5) Pages 1135 - 1141
DOI: http://dx.doi.org/10.2147/TCRM.S1155
Debra L Breneman1, Timothy J Storer2, John C Breneman3, Diya F Mutasim4
1University of Cincinnati Medical Center, Dept of Dermatology, Cincinnati, Ohio, USA; 2Smith Clinic, Delaware, Ohio, USA; 3University of Cincinnati Medical Center, Dept of Radiology, Division of Radiation Oncology, Cincinnati, Ohio, USA; 4University of Cincinnati Medical Center, Dept of Dermatology, Cincinnati, Ohio, USA
Abstract: Methotrexate-induced cutaneous ulceration has rarely been reported in patients with mycosis fungoides. We report 4 patients with mycosis fungoides who developed cutaneous ulceration as an initial manifestation of methotrexate toxicity. Methotrexate dose at the time of ulceration ranged from 10–60 mg. All 4 patients were erythrodermic, which may have predisposed them to this toxic effect. It is important to recognize cutaneous ulceration as an uncommon, but potentially serious, side effect of methotrexate in these patients, and to differentiate it from ulceration due to progressive lymphoma.
Keywords: mycosis fungoides, methotrexate, ulceration, cutaneous T-cell lymphoma, toxicity
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- American Acne and Rosacea Society
The American Acne and Rosacea Society (AARS), is a 501(c)(6) non-profit organization dedicated to elevating the understanding and treatment of acne and rosacea.
- Tenofovir-associated bone density loss
- The benefits and risks of testosterone replacement therapy: a review
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




